Abbott Laboratories (NYSE:ABT): Are Investors Getting Over Their Scepticism Over The Company's Bold US$21bn Bet On Exact Sciences?
Abbott Laboratories (NYSE:ABT): Are Investors Getting Over Their Scepticism Over The Company's Bold US$21bn Bet On Exact Sciences? Stocks Down Under
Covered in this story
What has happened since
- Abbott Laboratories is down 2.1% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Abbott Laboratories
- Citi: $101 → $112 by Jul 2027 via GuruFocus
- Piper Sandler: $101 → $118 by Jul 2027 · Overweight via GuruFocus
- Wells Fargo: $101 → $112 by Jul 2027 via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Abbott Laboratories →Dalsna Finance is currently tracking 49 stories mentioning Abbott Laboratories, the earliest published 17 Apr 2026.
Summary aggregated from Stocks Down Under's public RSS feed. The full reporting belongs to Stocks Down Under — please read it on their site.